News
RMTI
1.280
-0.78%
-0.010
Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer
Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Exec...
PR Newswire · 06/24 12:56
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/23 14:31
Rockwell Medical Receives Additional FDA Feedback On Anemia Candidate
Benzinga · 06/23 11:07
FDA requests microbial challenge study from Rockwell Medical for planned phase 2 trial
Rockwell Medical (NASDAQ:RMTI) on Wednesday said that the U.S. FDA had requested the company to perform a microbial challenge study for its planned phase 2 trial of its iron salt
Seekingalpha · 06/22 20:24
BRIEF-Rockwell Medical Files Preliminary Prospectus Related To Offering On A Resale Basis Of 11.2 Million Shares Of Common Stock By Selling Stockholders
BRIEF-Rockwell Medical Files Preliminary Prospectus Related To Offering On A Resale Basis Of 11.2 Million Shares Of Common Stock By Selling Stockholders
Reuters · 06/22 20:17
BRIEF-Rockwell Medical Provides Corporate And Clinical Update
BRIEF-Rockwell Medical Provides Corporate And Clinical Update
Reuters · 06/22 20:07
Rockwell Medical Provides Corporate and Clinical Update; Says Closed $7.5M 2nd Tranche Investment From DaVita, Raised $30M Total Capital This Quarter
Receives Additional Feedback from FDA on its IND Application Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and
Benzinga · 06/22 20:03
Rockwell Medical drops 14% as CEO departs
Rockwell Medical (NASDAQ:RMTI) shed ~14% in the pre-market Wednesday after the healthcare supplier announced the resignation of its President and Chief Executive Officer Russell Ellison effective June 30. Mark Strobeck is expected
Seekingalpha · 06/22 12:26
BRIEF-Rockwell Medical Inc Appoints Mark Strobeck As President And Chief Executive Officer
BRIEF-Rockwell Medical Inc Appoints Mark Strobeck As President And Chief Executive Officer
Reuters · 06/22 12:15
Rockwell Medical Names Mark Strobeck President, CEO; Shares Fall Pre-Bell
MT Newswires · 06/22 08:57
Rockwell Medical Closes $15 Million Financing from Leading Healthcare Investor
Rockwell Medical, Inc. (Nasdaq: RMTI) has closed the previously announced $15 Million in financing, consisting of $12 Million in a Registered Direct Offering, and $3 Million in a private investment in public equity (PIPE), both priced at-market, with Armis...
PR Newswire · 06/07 12:00
Rockwell Medical regains Nasdaq minimum bid price compliance
Rockwell Medical (NASDAQ:RMTI) was notified by the Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing. Rockwell is now in compliance with all applicable listing
Seekingalpha · 06/01 12:25
BRIEF-Rockwell Medical Regains Compliance With Nasdaq Listing Requirements
reuters.com · 06/01 12:18
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on May 31, 2022 informing...
PR Newswire · 06/01 12:00
Rockwell Medical Regains Compliance With Nasdaq's Minimum Bid Price Requirement; Shares Climb
MT Newswires · 06/01 11:22
Rockwell Medical Enters Securities Purchase Agreements With Armistice Capital Master Fund Ltd To Purchase $15M Of Common Stock And Warrants
WIXOM, Mich., May 31, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today
Benzinga · 05/31 12:11
Rockwell Medical launches $15M at-market offering
Rockwell Medical (NASDAQ:RMTI) has announced a $15M at-market offering. The biopharmaceutical company entered into securities purchase agreements with Armistice Capital Master Fund to purchase $15M of common stock (or common
Seekingalpha · 05/31 12:11
Rockwell Medical Signs Deals For $15 Million At-Market Offering With Armistice Capital Master Fund
MT Newswires · 05/31 10:18
Rockwell Medical, Inc. to Present at H.C. Wainwright Annual Global Life Sciences Conference
Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that Russell Ellison, M.D., M.Sc., President and Chie...
PR Newswire · 05/23 12:00
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Decisionpoint Systems, Inc. (NASDAQ: DPSI) rose 47.2% to $7.02 in pre-market trading after jumping around 19% on Tuesday. DecisionPoint Systems recently reported first-quarter FY22 revenue growth of 22.7% year-on-year to $19.7 million.
Benzinga · 05/18 10:06
More
Webull provides a variety of real-time RMTI stock news. You can receive the latest news about Rockwell Med Inc through multiple platforms. This information may help you make smarter investment decisions.
About RMTI
Rockwell Medical, Inc. is a commercial-stage, biopharmaceutical company. The Company is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. It is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The Company has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.